Cigna Healthcare
Cigna Healthcare is a global health services company offering health insurance, pharmacy benefits through Express Scripts (Evernorth), and related healthcare services. It serves approximately 170 million customer relationships worldwide across commercial, Medicare Advantage, Medicaid, and international markets.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
CIGNA Corporation was formed from the merger of Connecticut General and INA Corporation, creating one of the largest insurance companies in America. The health insurance industry was still largely indemnity-based with limited managed care penetration. Employer-sponsored coverage was structurally entrenched but market concentration was moderate, with dozens of regional insurers competing. Algorithmic claims processing and PBM consolidation had not yet begun.
Cigna completed its pivot to managed care under CEO Hanway, narrowing focus through the 1997 sale of life insurance operations to Lincoln National. The managed care model introduced utilization review, prior authorization requirements, and network restrictions that began constraining patient choice. Express Scripts, still independent, had grown to one of the largest PBMs through the 1990s, and the PBM industry was beginning to leverage formulary exclusions and mail-order steering to extract margins from drug manufacturers and pharmacies.
Express Scripts completed its $29 billion Medco acquisition, creating the dominant PBM controlling benefits for 135 million people. Cigna acquired HealthSpring for $3.8 billion, entering Medicare Advantage and beginning the upcoding schemes the DOJ would later prosecute. The PxDx algorithm was already operational, enabling bulk claim denials. The ACA established marketplace exchanges but also institutionalized annual open enrollment constraints. Health insurance market concentration was rising steadily, with 95% of MSA-level markets already highly concentrated.
Cigna's $67 billion acquisition of Express Scripts in December 2018 created a vertically integrated health services conglomerate controlling insurance, PBM, specialty pharmacy, and health analytics. The Anthem-Cigna mega-merger had been blocked on antitrust grounds in 2017, but vertical integration received lighter regulatory scrutiny. Express Scripts' spread pricing, rebate retention, and below-cost pharmacy reimbursement practices were now embedded within Cigna's corporate structure, creating self-dealing opportunities as the insurer steered members to its own pharmacy services.
ProPublica's March 2023 expose of the PxDx bulk denial system triggered congressional investigations, multiple class action lawsuits, and widespread media coverage of Cigna's automated claim rejection practices. In October, Cigna paid $172 million to settle DOJ Medicare Advantage upcoding fraud allegations spanning 2012-2021. The company conducted mass layoffs while reporting record revenues and announcing $10 billion in buybacks after abandoning Humana merger talks. CEO Cordani had received over $91 million in 2021 compensation.
The FTC sued Express Scripts over insulin pricing manipulation and secured a landmark settlement requiring elimination of spread pricing and transition to cost-plus reimbursement by 2028. The PxDx class action survived dismissal. The ghost network settlement exposed inaccurate provider directories trapping members. Michigan's antitrust suit alleged Express Scripts controlled nearly 90% of the state's PBM market. MultiPlan algorithmic collusion claims advanced in court with DOJ support. Despite regulatory pressure, Cigna reported $247 billion in revenue, repurchased $7 billion in shares, and continued aggressive financial engineering.
Alternatives
An integrated insurer-provider model with significantly lower claim denial rates and higher member satisfaction than Cigna. Because Kaiser employs its own doctors, the algorithmic denial dynamic exposed by the PxDx scandal is structurally absent — there's no adversarial insurer-vs-provider relationship. The catch: Kaiser is only available in 8 states and D.C., and you must use Kaiser's own network. If you live in a Kaiser service area and have marketplace or employer plan choice, it's the clearest structural alternative.
For Cigna Medicare Advantage enrollees: switching back to traditional fee-for-service Medicare paired with a Medigap supplemental policy eliminates prior authorization denials and algorithmic claim rejections. You can see any Medicare-accepting provider nationwide — no ghost network surprises. Moderate switch — requires comparing Medigap plan options and timing the move to a Medicare enrollment window. Generally costs more in premiums but delivers far fewer unexpected denials.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (45 events)
CIGNA formed from CG-INA merger
Connecticut General Corporation and INA Corporation merged to create CIGNA Corporation, combining CG's strength in life insurance and employee benefits with INA's property-casualty expertise. The $4.2 billion merger created one of the largest insurance and financial services companies in the United States, with dual CEOs Robert Kilpatrick and Ralph Saul.
Managed care enrollment surge restricts patient provider choice
By 1995, over 58 million Americans were enrolled in HMOs, up from 36.5 million in 1990, with the majority of employer-based insurance now in managed care. Cigna's managed care plans required referrals for specialists, restricted out-of-network coverage, and limited provider choices to contracted networks. Large numbers of employees were converted from fee-for-service coverage to HMO restrictions, often involuntarily and without full explanation of limitations.
Supreme Court limits ERISA preemption in Travelers decision
In New York State Conference of Blue Cross & Blue Shield v. Travelers Insurance Co., the Supreme Court curtailed ERISA's preemption reach, concluding that New York's hospital rate surcharges were not preempted. While nominally a setback for insurers, the ERISA framework continued to shield health plans like Cigna from most state-level consumer protection lawsuits throughout the 1990s, as courts generally upheld preemption for coverage denial claims.
Cigna sells life insurance operations to Lincoln National
Cigna divested the majority of its individual life insurance and annuity operations to Lincoln National Corporation, signaling a strategic pivot toward health insurance and managed care as the core business. This narrowing of focus concentrated Cigna's revenue streams on the higher-margin, more extractive health insurance segment.
Supreme Court upholds ERISA preemption for Cigna coverage denials
The U.S. Supreme Court ruled in Aetna Health Inc. v. Davila that state-law causes of action brought under the Texas Health Care Liability Act involving coverage decisions by Cigna Healthcare of Texas and Aetna were preempted by ERISA. The ruling reinforced that patients harmed by coverage denials from employer-sponsored plans could not sue in state court for damages, limiting accountability for insurer decision-making.
Express Scripts leverages rebate system to drive PBM revenue growth
Express Scripts' revenue model increasingly relied on manufacturer rebates retained by the PBM rather than passed through to plan sponsors or patients. By the late 2000s, the PBM rebate system had evolved from a cost-containment tool into a revenue extraction mechanism where PBMs like Express Scripts profited from higher list prices that generated larger rebate percentages, even as patient out-of-pocket costs tied to those list prices continued rising.
CEO Hanway retires with $110.9 million package
Outgoing CEO H. Edward Hanway received a retirement package totaling $110.9 million, including $18.8 million in 2009 compensation plus pension, deferred compensation, and stock options. The payout drew public outrage during a period when health insurance premiums were rising 10%+ annually and the national debate over healthcare reform was at its peak.
PxDx claim review system developed at Cigna
Cigna developed the PxDx (procedure-to-diagnosis) automated claim review system under Dr. Alan Muney. The system created a list matching approved procedures to specific diagnoses, automatically flagging mismatches for denial. Medical directors could then reject flagged claims in bulk without opening individual patient files, spending an average of 1.2 seconds per review.
Cigna acquires HealthSpring for $3.8 billion
Cigna acquired HealthSpring Inc. for approximately $3.8 billion in cash, adding nearly 340,000 Medicare Advantage members across 11 states and over 800,000 Medicare Part D customers. The acquisition transformed Cigna from a primarily employer-focused insurer into a major Medicare Advantage player, expanding its reach into the senior market with its higher-margin government-reimbursed plans.
Cigna begins Medicare Advantage 360 assessment program
Cigna contracted with vendors to conduct in-home '360 comprehensive assessments' of Medicare Advantage members, ostensibly for health monitoring. The DOJ later alleged these assessments were primarily designed to capture and record lucrative diagnosis codes that would inflate government reimbursement payments from CMS, rather than to improve patient care.
Express Scripts acquires Medco for $29 billion
Express Scripts completed its $29.1 billion acquisition of Medco Health Solutions, creating the largest PBM in the country controlling pharmacy benefits for approximately 135 million people. FTC Commissioner Brill called it a 'merger to duopoly' between ESI/Medco and CVS Caremark. The combined entity controlled roughly 60% of the mail-order pharmacy market, dramatically concentrating PBM market power that Cigna would later absorb.
Cigna disability claims handling investigation results in $77M settlement
Investigations by insurance departments in California, Maine, Connecticut, Pennsylvania, and Massachusetts found Cigna subsidiaries had improperly handled long-term disability claims, failing to use available information when processing claims and leading to wrongful denials and delays. Cigna entered a multi-state settlement making $77 million available for improperly denied disability claims from 2005-2007.
Express Scripts aggressively expands formulary exclusion lists
Express Scripts dropped 48 brand-name drugs from its standard national preferred formulary for 2014, with Chief Medical Officer Steven Miller declaring the company would be 'more aggressive this year' with exclusions. The exclusion strategy affected 30 million members on the national preferred formulary, using the threat of formulary removal to extract larger rebates from drug manufacturers.
Cigna enters ACA marketplace exchanges
Cigna began offering individual and family health plans on the Affordable Care Act marketplace exchanges in their initial year. While expanding consumer access, the ACA's annual open enrollment windows also institutionalized the once-per-year switching constraint that adds to health insurance lock-in. Cigna initially offered plans in a limited number of states before gradually expanding.
Cigna launches chart review program for Medicare upcoding
From 2014 to 2019, Cigna operated a 'chart review' program that obtained beneficiary medical charts from physicians and submitted additional diagnosis codes to CMS for higher reimbursement payments. The DOJ later alleged that the added diagnoses were often unsubstantiated, constituting a systematic scheme to inflate Medicare Advantage payments.
Anthem announces $47 billion acquisition of Cigna
Anthem Inc. (now Elevance Health) announced a definitive agreement to acquire Cigna for approximately $47 billion in cash and stock. The proposed mega-merger would have combined two of the five largest U.S. health insurers, further concentrating the already highly concentrated commercial insurance market.
Express Scripts conducts post-Medco integration layoffs
Express Scripts carried out workforce reductions as part of the post-Medco integration, eliminating positions at the Columbus pharmacy site and other locations. Employees who had worked through the Merck-Medco to Medco to Express Scripts transitions found themselves laid off as the company pursued the $600 million in 'retained synergies' promised in its merger filings. The consolidation pattern of acquiring competitors and cutting redundant staff became a recurring feature of PBM industry concentration.
Federal judge blocks Anthem-Cigna merger on antitrust grounds
U.S. District Judge Amy Berman Jackson blocked the proposed $54 billion Anthem-Cigna merger, ruling it would substantially reduce competition in the sale of health insurance to national accounts. The DOJ's antitrust division argued the deal violated Section 7 of the Clayton Act. Anthem abandoned the acquisition attempt in May 2017 after an appeals court upheld the ruling.
Cigna announces $67 billion Express Scripts acquisition
Cigna announced a definitive agreement to acquire Express Scripts, the nation's largest pharmacy benefit manager, for approximately $67 billion including $15 billion in assumed debt. The deal created a vertically integrated health services company combining insurance, PBM, specialty pharmacy, and health analytics under one corporate umbrella, raising immediate concerns about self-dealing and anticompetitive steering.
Express Scripts and Prime Therapeutics enter pharmacy reimbursement agreement
Express Scripts and Prime Therapeutics signed an agreement for Prime to adopt Express Scripts' lower pharmacy reimbursement rates in exchange for accessing Express Scripts' buying power. The Michigan Attorney General later alleged this arrangement constituted a price-fixing conspiracy that drove independent pharmacies out of business and created pharmacy deserts in Detroit and rural Michigan communities.
Accredo specialty pharmacy steering locks patients into Cigna-owned services
Following the Express Scripts integration, Cigna/Evernorth increasingly required patients taking specialty medications to exclusively use Accredo, its in-house specialty pharmacy, rather than allowing independent specialty pharmacies. Patients on life-sustaining medications for cancer, multiple sclerosis, and organ-transplant rejection reported having no choice but to use Accredo, creating pharmaceutical lock-in within Cigna's vertically integrated system. Accredo had previously paid $60 million to settle kickback and false claims allegations.
Medicare Advantage prior authorization denial rates climb steadily
Medicare Advantage prior authorization denial rates increased from 5.7% in 2019 to 5.8% in 2021 before jumping to 7.4% in 2022, reflecting an industry-wide trend of escalating administrative barriers. Surveys found 82% of providers reported increasing prior authorization requirements from insurers including Cigna, with 94% of physicians experiencing care delays and 78% reporting treatment abandonment as a direct result of the prior authorization burden.
Cigna rebrands health services division as Evernorth
Cigna rebranded its growing health services segment, including Express Scripts, specialty pharmacy Accredo, and utilization management firm eviCore, as Evernorth Health Services. The consolidation under a single brand obscured the extent of vertical integration from consumers while streamlining cross-selling across pharmacy, benefit management, and care solutions.
CEO Cordani receives over $91 million in total compensation
Cigna CEO David Cordani's total realized compensation for 2021 exceeded $91 million, making him the highest-paid U.S. health insurance executive. While Cigna's proxy statement reported $19.87 million, actual gains from exercised stock options and other components brought the true figure to $91 million. This occurred while the company was processing claims through the PxDx system that denied hundreds of thousands of claims per month.
Express Scripts spread pricing peaks as rebate-based model maximizes extraction
By 2021, Express Scripts' rebate-based pricing model had matured into peak extraction mode. While utilization drove overall drug spending growth, Express Scripts expanded 'copay maximizer' programs that captured manufacturer copay assistance rather than passing it to patients. The PBM charged payers prices above what it reimbursed pharmacies through spread pricing, while simultaneously retaining portions of manufacturer rebates, extracting margin from both sides of each prescription transaction.
AMA joins class action against Cigna over underpayments via MultiPlan
The American Medical Association, Medical Society of New Jersey, and Washington State Medical Association became plaintiffs in a class action alleging Cigna used Zelis to unilaterally re-price out-of-network claims far below MultiPlan contracted rates. The suit alleged Cigna earned higher 'savings' fees by paying less than contractually required, leaving patients exposed to balance billing.
ProPublica exposes PxDx bulk claim denial system
ProPublica published an investigation revealing that Cigna's PxDx algorithm enabled medical directors to deny over 300,000 claims in a two-month period, spending an average of 1.2 seconds per review. A single doctor denied up to 60,000 claims per month without opening patient files. Internal documents showed Cigna estimated only 5% of denials would be appealed, yet 80% of appealed denials were overturned.
Cigna announces enterprise-wide 14% workforce reduction
Cigna's enterprise organization underwent a 14% reduction affecting both full-time employees and contractors, citing performance alignment and budget concerns. Affected full-time employees received five months of severance plus one additional month of pay. Additional rounds of layoffs followed through October 2023, contributing to seven consecutive months of workforce reductions.
Congressional committee and regulators launch PxDx investigation
The House Energy and Commerce Committee joined state and federal regulators in investigating Cigna's PxDx system after ProPublica's reporting. Congressional Republicans pressed Cigna for clarification on how the system operated. The Senate Homeland Security Subcommittee on Investigations held hearings examining Medicare Advantage denial patterns across the industry, with Cigna's practices drawing particular scrutiny.
First PxDx class action lawsuit filed against Cigna
A class action lawsuit was filed in California federal court alleging Cigna used the PxDx system to batch-deny claims knowing members likely would not fight the decisions. The suit charged that Cigna's automated denials violated ERISA fiduciary duties by substituting algorithmic processing for the individualized medical judgment promised in plan documents.
Data breach via Prospect Medical exposes Cigna member information
Between July 31 and August 3, 2023, unauthorized parties accessed the network of Prospect Medical Holdings and acquired files containing confidential Cigna health plan member information. Exposed data included names, Social Security numbers, diagnoses, lab results, medications, treatment information, and financial details. Cigna did not notify affected members until January 2024.
Cigna pays $172 million to settle Medicare Advantage upcoding fraud
The Cigna Group agreed to pay $172,294,350 to resolve DOJ False Claims Act allegations that it submitted fraudulent diagnosis codes for Medicare Advantage enrollees between 2012 and 2021. The fraud involved three schemes: the 360 in-home assessment program, a chart review program that added unsubstantiated diagnoses, and inaccurate morbid obesity coding. Cigna entered a five-year Corporate Integrity Agreement with HHS OIG.
Cigna abandons Humana merger, announces $10 billion buyback
After months of negotiations over a potential $60+ billion merger with rival Humana that would have created a company valued at over $140 billion, Cigna abandoned the deal, reportedly because the parties could not agree on price. The hot antitrust environment following the blocked 2017 Anthem-Cigna deal also loomed. Cigna immediately announced $10 billion in additional share repurchases, using the freed capital for shareholder extraction rather than operational investment.
Cigna announces 2,000-employee global workforce reduction
Cigna HR leadership announced plans to eliminate approximately 2,000 roles globally, representing less than 3% of the enterprise workforce, with implementation through February 2024. The layoffs came while the broader healthcare industry was adding tens of thousands of jobs and followed seven consecutive months of prior reductions in 2023. Glassdoor reviews described destroyed company culture and impossible workload expectations for remaining staff.
Cigna return-to-office mandate drives talent departures
Cigna enforced a return-to-office mandate requiring employees hired as fully remote to work from offices if they lived within 50 miles, including those with remote work specified in their offer letters. HR threatened employees with badge scanning and disciplinary action. Glassdoor reviews described the mandate as torpedoing morale, with experienced staff leaving rather than complying, compounding the impact of concurrent layoffs.
MultiPlan algorithmic pricing antitrust claims survive dismissal
U.S. District Judge Matthew Kennelly denied motions to dismiss antitrust claims against MultiPlan and insurer defendants including Cigna, ruling that plaintiffs plausibly alleged that MultiPlan's Data iSight algorithm facilitated a horizontal price-fixing agreement among insurers to suppress out-of-network provider reimbursement rates. The DOJ filed a statement of interest supporting the plaintiffs' algorithmic collusion claims.
Ghost network class action filed against Cigna
Andrew and Andrea Hecht filed an ERISA class action in Illinois federal court alleging Cigna's online provider directory constituted a 'ghost network' — listing providers as in-network who were actually unreachable, out-of-network, or non-existent. Members who relied on the directory for care selection received surprise out-of-network bills amounting to thousands of dollars, with some suffering credit damage.
FTC sues Express Scripts over anticompetitive insulin pricing
The Federal Trade Commission sued Express Scripts, CVS Caremark, and OptumRx for engaging in anticompetitive rebating practices that artificially inflated insulin list prices. The FTC alleged PBMs created a system where manufacturers competed for formulary placement through larger rebates rather than lower net prices. From 1999 to 2017, the average list price of Humalog rose from $21 to over $274 — a 1,200% increase driven in part by the rebate-chasing system.
Cigna prices 2025 health plans with above-normal cost increases
Cigna announced that its 2025 health plan pricing reflected 'higher than normal' cost increases, with ACA marketplace rate hikes of 10-15% in several states. The rate increases were attributed to rising healthcare costs, particularly specialty pharmacy spending through Evernorth, though critics noted the company simultaneously reported record quarterly revenues and continued aggressive share buyback programs.
Cigna reports $247 billion revenue with $7 billion in buybacks
The Cigna Group reported full-year 2024 revenues of $247.1 billion, a 27% increase driven primarily by Evernorth Health Services growth. The company repurchased 20.9 million shares for approximately $7 billion and the board authorized an additional $6 billion in repurchase authority. CEO Cordani earned $23.3 million with a 279:1 CEO-to-median-worker pay ratio, occurring alongside the 2,000+ employee layoffs announced the same month a year prior.
Cigna completes $3.7 billion Medicare business sale to HCSC
Cigna completed the sale of its Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses to Health Care Service Corporation for $3.7 billion. The divestiture covered nearly 600,000 Medicare Advantage members and 3.6 million total Medicare members. Cigna stated the majority of proceeds would fund share repurchases, while Evernorth continued serving Medicare pharmacy benefits through service agreements.
PxDx class action survives motion to dismiss in federal court
U.S. District Judge Kimberly Mueller allowed the PxDx class action to proceed, finding sufficient evidence that Cigna's automated algorithm substituted for genuine medical judgment. The ruling permitted breach of fiduciary duty claims under ERISA to advance, noting that the PxDx system denied claims based on diagnosis-procedure code mismatches without individualized review while presenting decisions as physician-reviewed.
Michigan AG files antitrust suit against Express Scripts
The Michigan Attorney General filed an antitrust lawsuit in federal court against Express Scripts and Prime Therapeutics, alleging a conspiracy to fix pharmacy reimbursement rates and drive independent pharmacies out of business. The complaint alleged Express Scripts controlled nearly 90% of Michigan's PBM market and that the conspiracy created pharmacy deserts in half of Detroit's neighborhoods and rural communities.
Cigna settles ghost network lawsuit for $5.7 million
Cigna agreed to pay $5.7 million to resolve the ERISA class action alleging that inaccurate provider directories created a 'ghost network' that misled members into believing certain providers were in-network. A federal judge granted preliminary approval of the settlement, which established a constructive common fund providing injunctive relief and class benefits for members who received surprise out-of-network bills after relying on Cigna's directory.
FTC secures landmark settlement with Express Scripts
The FTC reached a settlement requiring Express Scripts to eliminate spread pricing, pass manufacturer rebates directly to patients at point of sale beginning in 2028, and base pharmacy reimbursements on actual drug cost plus dispensing fees. The deal was projected to lower patients' out-of-pocket costs by up to $7 billion over a decade. Express Scripts must also increase transparency reporting to plan sponsors and delink manufacturer payments from list prices.